Alzheimer’s Disease

Gain accurate and reliable quantitative data with our endpoint ELISA assays. Our AD Panel offers robust and reproducible ELISA data, enabling researchers to measure protein levels and detect changes in established biomarkers critical for AD research.

Our Alzheimer’s Disease Panel provides valuable insights into patient-specific drug responses. Our healthy donor-derived excitatory neurons consistently respond to a GSK3β inhibitor, showing uniform sensitivity (see figure below). In contrast, AD patient-derived excitatory neurons exhibit high variability in drug response, mirroring the diversity seen in patients. This emphasizes the translational potential of our AD models, as they closely replicate the genetic and phenotypic diversity of the patient population. Such models are essential for identifying genetic determinants of drug resistance and improving patient stratification.

Cohen’s D quantifies how effectively a drug differentiates patient populations based on gene variants. A high Cohen’s d indicates gene variants that play a critical role in differentiating patient subgroups, enabling informed decisions on drug efficacy and patient stratification. 

Thresholds for interpretation:

• Small effect (𝑑=0.2: Minimal difference, limited relevance for stratification.
• Medium effect (𝑑=0.5): Moderate differentiation, potentially meaningful.
• Large effect (𝑑=0.8+): Strong differentiation, high importance for stratification.